Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Q4 2024 Earnings Presentation
15 slides from Syndax Pharmaceuticals's earnings presentation, Mar 3, 2025
Slide 1: Fourth Quarter & Full Year 2024 Financial Results Presentation
Fourth Quarter & Full Year 2024 Financial Results Presentation / March 3, 2025
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Syndax is executing as a commercial oncology company with two first-in-class medicines
Syndax is executing as a commercial oncology company with two first-in-class medicines that address major unmet needs RECENT ACHIEVEMENTS Strong Start to Revuforj U.S. Launch Syndax is executing as a • $7.7 M in net revenue in 4Q24 (initial 5 weeks of U.S. launch) commercial oncology company with tw
Slide 4: U.S. launch of Revuforj is off to a strong start
U.S. launch of Revuforj is off to a strong start driven by excellent commercial execution and high unmet need 4Q24 REVUFORJ NET REVENUE RESULTS REFLECT: ✓ Excellent commercial execution $7.7 M ✓ Urgent patient need in initial 5 weeks of U.S. launch ✓ High product awareness Includes inventory at spec
Slide 5: Encouraging early breadth and depth of Revuforj prescribing and favorable payer coverage
Encouraging early breadth and depth of Revuforj prescribing and favorable coverage from payers ✓ 33% of Tier 1/Tier 2 accounts have ordered PRESCRIBERS ✓ Orders from leading academic institutions and community practices END OF FEB 2025 across the U.S. and major metropolitan areas ✓ Patient mix is co
Slide 6: Revuforj is well positioned for near-term and long-term growth and success
Revuforj is well positioned for near-term and long-term growth and success CRITICAL SUCCESS FACTORS First mover advantage Compelling safety & efficacy profile Included in NCCN Guidelines® for AML & ALL First and only menin inhibitor with positive pivotal data in: First-in-class menin inhibitor • R/R
Slide 7: U.S. launch of Niktimvo is underway
U.S. launch of Niktimvo is underway WELL-POSITIONED FOR SUCCESS Novel MoA in chronic GVHD to address inflammation and fibrosis Responses were rapid, durable & observed across all organs studied Included in NCCN Guidelines® Co-commercializing with the leader First-in-class anti-CSF-1R-blocking antibo
Slide 8: Well positioned to receive an indication in R/R mNPM1 AML
Syndax is well positioned to receive an indication in R/R mNPM1 AML, further securing our competitive advantage Completed milestones Reported consistent results in a larger Anticipated milestones population (N=77) ORR = 48% and CR/CRh = 26% Submit sNDA to FDA Dec 2024 2Q 2025 Nov 2024 2Q 2025 ~YE 20
Slide 9: Rapidly advancing development of revumenib across the treatment continuum
Syndax is rapidly advancing the development of revumenib across the treatment continuum for genetically defined acute leukemias RELAPSED / FRONTLINE MAINTENANCE REFRACTORY “UNFIT” “FIT” Ph 2 HOVON Trial AUGMENT-101 Rev + I.C./S.O.C. Rev maintenance or 3 Rev + ven/aza Rev monotherapy ✓ Pivotal trial
Slide 10: Poised to lead menin inhibition in frontline mNPM1 and KMT2Ar acute leukemias
Syndax is poised to lead the development of menin inhibition for the frontline treatment of mNPM1 and KMT2Ar acute leukemias In the frontline unfit population, Syndax is initiating a pivotal trial of revumenib + ven/aza in collaboration with the HOVON network UNFIT Rev + ven/aza Pivotal trial builds
Slide 11: Financial highlights: 4Q24
Financial highlights: 4Q24 Three Months Ended December 31 Key 4Q24 Financial Results (Unaudited) (in millions) 2024 2023 Revuforj net sales $7.7 -- Cost of product sales 0.8 -- Research & development 65.5 55.1 Selling, general and administrative 37.7 22.8 Total costs and operating expenses $104.0 $7
Slide 12: Accounting for net profits/losses on sales of Niktimvo: Illustrative example
Accounting for net profits/losses on sales of Niktimvo: Illustrative example Syndax will report collaboration profits on a net basis; Incyte will record product sales Net Profit Example: Niktimvo Assumption Syndax Illustrative P&L Net product sales of Niktimvo $ 1,000 Collaborative Arrangement Reven
Slide 13: Expected upcoming milestones
Revuforj (revumenib) Menin-KMT2A inhibition • Maximize U.S. adoption of Revuforj as the preferred menin inhibitor • Submit sNDA in R/R mNPM1 AML in 2Q25, with potential approval around YE 2025 • Publish pivotal R/R mNPM1 AML data and submit publication to NCCN Guidelines in 2Q25 • Initiating a pivot
Slide 14: Determined to realize a future in which people with cancer live longer and better
Determined to realize a future in which people with cancer live longer and better than ever before. 14
Slide 15: Slide 15
Syndax Pharmaceuticals — Q4 2024 Earnings Presentation on 6ix